Erratum: Site-specific stabilization of minigastrin analogs against enzymatic degradation for enhanced cholecystokinin-2 receptor targeting: Erratum.

Journal

Theranostics
ISSN: 1838-7640
Titre abrégé: Theranostics
Pays: Australia
ID NLM: 101552395

Informations de publication

Date de publication:
Historique:
entrez: 2 8 2019
pubmed: 2 8 2019
medline: 2 8 2019
Statut: epublish

Résumé

[This corrects the article DOI: 10.7150/thno.24378.].

Identifiants

DOI: 10.7150/thno.36746 PMID: 31367242 PMC: PMC6643442
pubmed: 31367242
doi: 10.7150/thno.36746
pii: thnov09p4595
pmc: PMC6643442
doi:

Types de publication

Published Erratum

Langues

eng

Sous-ensembles de citation

IM

Pagination

4595-4596

Subventions

Organisme : Austrian Science Fund FWF
ID : P 27844
Pays : Austria

Commentaires et corrections

Type : ErratumFor

Références

Theranostics. 2018 Apr 16;8(11):2896-2908
pubmed: 29896292

Auteurs

Maximilian Klingler (M)

Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria.

Clemens Decristoforo (C)

Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria.

Christine Rangger (C)

Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria.

Dominik Summer (D)

Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria.

Julie Foster (J)

Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.

Jane K Sosabowski (JK)

Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.

Elisabeth von Guggenberg (E)

Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria.

Classifications MeSH